Did Amy Schumer confirm she used a GLP-1 medication?

Yes. Schumer publicly confirmed in 2023 that she used Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, and later discontinued it due to side effects.

Why did Amy Schumer stop taking Mounjaro?

Schumer stated she experienced intolerable side effects. Her public descriptions were consistent with the gastrointestinal adverse effects commonly associated with tirzepatide, including nausea and digestive disruption.

Is it common to stop GLP-1 medications due to side effects?

Yes. Clinical trials report discontinuation rates of 4-7% due to adverse events for tirzepatide, and real-world data suggests even higher attrition. Gastrointestinal symptoms are the leading cause of GLP-1 discontinuation.

Is Mounjaro the same as Ozempic?

No. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist made by Eli Lilly. Ozempic (semaglutide) is a pure GLP-1 receptor agonist made by Novo Nordisk. Both produce weight loss and improve glycemic control, but they have different receptor targets and side-effect profiles.

Can you switch from Mounjaro to another GLP-1 if side effects are intolerable?

Switching within the GLP-1 class is a recognized clinical strategy. Some patients who cannot tolerate tirzepatide do better on semaglutide or liraglutide, and vice versa. Individual pharmacologic response varies, and a trial of an alternative agent is reasonable before concluding that the entire drug class is unsuitable.

Amy Schumer and GLP-1: The Documented Public Record

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

The Confirmed Public Record

Amy Schumer disclosed her experience with Mounjaro through Instagram posts and podcast appearances in 2023. She stated directly that she had used the medication, that it was prescribed for weight management following the birth of her son Gene (born May 2019), and that she stopped taking it because the side effects were more than she could tolerate.

This is a confirmed case. Schumer herself named the drug, described taking it, and explained why she quit. There is no ambiguity or speculation required here.

Her account was notable for its bluntness. At a time when many public figures were being evasive about whether they used GLP-1 receptor agonists, Schumer talked openly about both trying the medication and finding it unworkable. She described gastrointestinal symptoms that made daily functioning difficult, consistent with the known adverse-effect profile of tirzepatide.

At a glance

Drug confirmed: Mounjaro (tirzepatide)
Purpose stated: Postpartum weight management
Outcome: Discontinued due to intolerable side effects
Year of disclosure: 2023
Method of disclosure: Instagram, podcast interviews
Current GLP-1 status: Not publicly using any GLP-1 medication

What Is Mounjaro and How Does It Work?

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. Unlike semaglutide (Ozempic, Wegovy), which acts on the GLP-1 receptor alone, tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism was hypothesized to produce greater weight loss and improved glycemic control compared to single-receptor agonists.

The FDA approved tirzepatide for type 2 diabetes (as Mounjaro) in May 2022 and later for chronic weight management (as Zepbound) in November 2023. Clinical trials demonstrated mean weight loss of 15% to 22.5% of body weight at the highest doses in the SURMOUNT-1 trial, published in the New England Journal of Medicine.

Tirzepatide is administered as a once-weekly subcutaneous injection. The prescribing protocol starts at 2.5 mg weekly for four weeks, then escalates in 2.5 mg increments every four weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg, depending on tolerability and clinical response.

The Side-Effect Profile Schumer Described

Schumer's public statements focused on gastrointestinal distress. While she did not provide a clinical inventory of every symptom, her descriptions aligned with the most commonly reported adverse effects of tirzepatide.

According to FDA prescribing information, the most frequent adverse reactions in tirzepatide clinical trials included:

Nausea (reported in 12% to 33% of participants, dose-dependent)
Diarrhea (12% to 23%)
Decreased appetite (9% to 16%)
Vomiting (5% to 13%)
Constipation (6% to 11%)
Dyspepsia (5% to 9%)
Abdominal pain (5% to 7%)

The SURMOUNT trials showed that approximately 4.3% to 7.1% of participants discontinued tirzepatide due to adverse events, compared to 2.6% for placebo. Gastrointestinal events were the primary driver of discontinuation. A pooled analysis published in The Lancet confirmed that GI-related treatment discontinuation was highest during the dose-escalation phase.

The HealthRX Medical Team Clinical Perspective

The HealthRX Medical Team views Schumer's experience as clinically instructive for several reasons.

Dose-escalation timing matters. Most GI side effects peak during the first weeks after each dose increase. Patients who escalate too quickly, or whose prescribers skip the recommended four-week intervals, face substantially higher intolerability risk. We do not know what titration schedule Schumer followed, but her rapid discontinuation suggests either a compressed escalation or pronounced sensitivity at lower doses.

Individual variability is real and underappreciated. Population-level trial data showing 5-7% discontinuation rates can obscure the intensity of symptoms for those in the tail of the distribution. A patient experiencing persistent vomiting or severe nausea is not experiencing a "mild and transient" side effect, even if most trial participants tolerated the drug adequately.

The postpartum context adds complexity. Postpartum physiology involves shifting hormone levels, potential breastfeeding considerations, sleep disruption, and altered gut motility. Published data on GLP-1 agonist use specifically in the postpartum period remains limited. The Endocrine Society's 2023 guidelines on pharmacotherapy for obesity do not specifically address postpartum initiation timing.

Discontinuation is a valid clinical outcome. The cultural narrative around GLP-1 medications in 2023-2024 often framed discontinuation as failure. From a clinical standpoint, stopping a medication that produces intolerable adverse effects is appropriate medical decision-making. Persistence with therapy should not come at the cost of quality of life when the indication is elective weight management rather than acute metabolic disease.

What Schumer's Case Does Not Tell Us

Several clinical questions remain unanswered by the public record:

What dose she reached before discontinuing
Whether she attempted dose reduction rather than full discontinuation
Whether her prescriber discussed switching to a pure GLP-1 agonist (semaglutide) as an alternative
Whether she experienced any of the rarer adverse effects (pancreatitis symptoms, injection-site reactions, gallbladder events)
Her metabolic parameters before and during treatment

These gaps are appropriate. Medical details beyond what a public figure volunteers are private, and speculation about undisclosed clinical information falls outside our editorial scope.

GLP-1 Intolerability: What the Literature Shows

A 2023 real-world study published in JAMA Network Open examining GLP-1 RA persistence found that roughly 40-50% of patients prescribed these medications for weight loss discontinued within 12 months. Reasons included side effects, cost, access issues, and perceived lack of efficacy.

Predictors of GLP-1 intolerability identified in clinical literature include:

Female sex (higher rates of nausea across multiple trials)
Lower baseline BMI
History of gastroparesis or functional GI disorders
Rapid dose escalation
Concurrent medications affecting gastric motility

For patients who cannot tolerate one GLP-1-class medication, switching within the class sometimes yields better results. Tirzepatide and semaglutide have distinct receptor-binding profiles, and individual response varies. Some patients tolerate daily liraglutide (Saxenda) at low doses better than weekly injectables, though the total weight loss achieved tends to be lower.

The Broader Context: Celebrity Disclosure and GLP-1 Stigma

Schumer's disclosure occurred during a period of intense public debate about GLP-1 medications. Throughout 2023, speculation about which celebrities were using Ozempic or similar drugs became a fixture of tabloid coverage. Many public figures denied use or refused to comment.

Schumer's approach was different: confirm, describe the experience honestly, and explain why it didn't work for her. This provided a public data point that countered the impression that these medications work seamlessly for everyone. The reality, supported by trial data, is that a meaningful minority of patients either cannot tolerate GLP-1 receptor agonists or find that the side-effect burden outweighs the benefit for their specific clinical situation.

Frequently asked questions

›

References

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
FDA. Mounjaro Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/
Endocrine Society. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. 2023. https://www.endocrine.org/clinical-practice-guidelines/obesity
Gasoyan H, et al. Early Discontinuation of GLP-1 Receptor Agonists. JAMA Network Open. 2023. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2806948